Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of inhibitors of miRNA-182, miRNA-188 and miRNA-199a

A technology of miRNA-199a and miRNA-188, applied in the direction of medical preparations containing active ingredients, organic active ingredients, nervous system diseases, etc., to reduce the formation of Aβ, improve plasticity, and improve the effect of learning and memory

Pending Publication Date: 2020-08-25
SHIHEZI UNIVERSITY +1
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Various treatments for Alzheimer's disease have been developed and advanced to late clinical trials in AD patients, but so far, no drug has been proven effective in large phase III trials

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of inhibitors of miRNA-182, miRNA-188 and miRNA-199a
  • Application of inhibitors of miRNA-182, miRNA-188 and miRNA-199a
  • Application of inhibitors of miRNA-182, miRNA-188 and miRNA-199a

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0016] 1. Detection and determination of specifically up-regulated miRNAs in AD model mice

[0017] 1. Take materials from hippocampus and cortex

[0018] Animals were sacrificed by cervical dislocation, and brain tissues were removed. The brain tissue was washed with saline at 4°C, and then dried with absorbent paper. The left and right hippocampus and cerebral cortex were taken out, rinsed with 4°C saline, dried with absorbent paper, and numbered.

[0019] 2. RNA extraction and detection

[0020] 3. First-strand cDNA reverse transcription

[0021] 1) The specific primers (designed by Primer Premier 5.0 software) designed for U6 and other miRNAs used in the reverse transcription of the first-strand cDNA, the primer sequences are shown in Table 1:

[0022] Table 1 Primer name and sequence

[0023]

[0024] 2) Add the following reagents to the nuclease-free PCR tube in ice bath, as shown in Table 2:

[0025] Table 2 PCR reaction system

[0026]

[0027] 3) Gently m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
Login to View More

Abstract

The invention relates to the technical field of biomedicine technology, and particularly discloses application of inhibitors of miRNA-182, miRNA-188 and miRNA-199a. The therapeutic effect of a miRNA inhibitor AM-182 / 188 / 199a on AD is clarified, specifically, the neuronal function of the hippocampus of AD mice and the plasticity of neuronal neurites are improved, the formation of A[beta] is reduced, the learning and memory ability of the AD mice are improved, new prevention and treatment methods are provided for the clinical treatment of AD, and new ideas are provided for the preparation of drugs for the treatment of AD.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of inhibitors of miRNA-182, miRNA-188 and miRNA-199a. Background technique [0002] Alzheimer's disease (AD) is a neurodegenerative disease characterized by impairment of learning and memory. The accumulation of β-amyloid protein and hyperphosphorylated tau protein, acetylcholine neurotransmitter, occurs in the brain of patients. reduction in cellular and molecular changes such as inflammation and oxidative stress. The accumulation of β-amyloid (Aβ) in extracellular plaques and hyperphosphorylated tau protein leading to intracellular neurofibrillary tangles are the most typical pathological features of AD. Various treatments for Alzheimer's disease have been developed and advanced to late clinical trials in AD patients, but so far, no drug has been proven effective in large phase III trials. AD drug development failure rate is 99%; AD disease-modifying thera...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7105A61P25/28
CPCA61K31/7105A61P25/28
Inventor 黄瑾杨磊朱井玲宋丹丹孙嘉伟
Owner SHIHEZI UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com